Welcome to Loot.co.za!
Sign in / Register |Wishlists & Gift Vouchers |Help | Advanced search
|
Your cart is empty |
|||
Showing 1 - 6 of 6 matches in All Departments
There are more than 63,000 new cases of uterine and endometrial cancer each year in the United States, up from approximately 41,000 when the first edition of Uterine Cancer was published in 2009. A book focusing on these cancers was timely, with emergent sophistication in diagnosis increasingly impacting clinical decision-making. However, five years later, the need for an updated book on this topic is even stronger as oncologists recognize opportunities to impact the outcome on women that are increasingly diagnosed with these malignancies. Uterine Cancer: Screening, Diagnosis, and Treatment, Second Edition, part of the Current Clinical Oncology series, enhances the awareness on this somewhat neglected area of therapeutics, helping to integrate targeted therapies into the management of women with uterine cancer. Written by experts in the field in a highly practical and comprehensive manner, it is a must-have for all gynecological residents and fellows, as well as gynecological oncologists, medical oncologists, radiation oncologists, and family practice doctors who wish to provide their patients with the best possible care.
Since the publication of the Third Series Fascicle of the Uterine Corpus nearly thirty years ago, molecular discoveries have deepened our understanding of epithelial, mesenchymal, and mixed mullerian tumors of the uterus, fueling a new and still evolving classification of the different categories of uterine neoplasms. Enormous insights have been made to refine the classification of the different subtypes of endometrial carcinoma linked to important prognostic and therapeutic implications. At the same time, molecular findings have allowed for the discovery of familial syndromes associated with uterine corpus neoplasms, and identification of patients at increased risk for developing specific tumors, with the subsequent implementation of genetic counseling and appropriate treatment guidelines. Molecular underpinnings have also assisted in the development of new and potentially more predictive morphologic criteria for endometrial preneoplasia, namely the endometrial intraepithelial neoplasia (or EIN) system. In this Uterine Corpus Fascicle, there is an increased emphasis on the cytopathologic (intraoperative, exfoliative, or fine needle aspiration) and molecular features that are important in diagnosis and prognosis. What does not change from the three previous series, however, is the goal of providing the reader with thorough, concise, and up-to-date information on the nomenclature and classification; epidemiologic, clinical, and pathogenetic features; and, most importantly, guidance in the diagnosis of the tumors and tumorlike lesions of all major organ systems and body sites. Order the Tumors of the Uterine Corpus and Trophoblastic Diseases now to take advantage of these new discoveries and techniques for diagnosing and treating these types of tumors.
This expert volume in the Diagnostic Pathology series is an excellent point-of-care resource for practitioners at all levels of experience and training. Covering the full range of nonneoplastic and neoplastic conditions of the female genital tract, it incorporates the most recent scientific and technical knowledge in the field to provide a comprehensive overview of all key issues relevant to today's practice. Richly illustrated and easy to use, the third edition of Diagnostic Pathology: Gynecological is a visually stunning, one-stop resource for every practicing pathologist, resident, student, or fellow as an ideal day-to-day reference or as a reliable training resource. Covers all areas of gynecologic pathology, organized into six easy-to-reference anatomic Covers all areas of gynecologic pathology, organized into seven easy-to-reference anatomic sections: vulva, vagina, uterine cervix, uterine corpus, fallopian tube and broad ligament, ovary, and peritoneum Includes all frequently encountered conditions plus extensive coverage of uncommon entities, such as inflammatory diseases of the vulva, discussed by experts in dermatopathology Provides updated differential diagnoses and diagnostic pearls as well as extensive revisions based on the 2020 WHO Classification of Tumors: Female Genital Tumors, including staging issues and measurement standards Reflects important molecular updates in endometrial carcinoma classifications as well as updated classifications for squamous and glandular tumors for the lower genital tract, both in situ and invasive Updates ancillary techniques, newly encountered pitfalls, and advances in the molecular landscape of epithelial and mesenchymal tumors Features more than 2,500 superb images in print and online, including many new gross and microscopic images as well as diagnostically relevant immunohistochemical and molecular findings Includes an eBook version that enables you to access all text, figures, and references, with the ability to search, customize your content, make notes and highlights, and have content read aloud
There are more than 63,000 new cases of uterine and endometrial cancer each year in the United States, up from approximately 41,000 when the first edition of Uterine Cancer was published in 2009. A book focusing on these cancers was timely, with emergent sophistication in diagnosis increasingly impacting clinical decision-making. However, five years later, the need for an updated book on this topic is even stronger as oncologists recognize opportunities to impact the outcome on women that are increasingly diagnosed with these malignancies. Uterine Cancer: Screening, Diagnosis, and Treatment, Second Edition, part of the Current Clinical Oncology series, enhances the awareness on this somewhat neglected area of therapeutics, helping to integrate targeted therapies into the management of women with uterine cancer. Written by experts in the field in a highly practical and comprehensive manner, it is a must-have for all gynecological residents and fellows, as well as gynecological oncologists, medical oncologists, radiation oncologists, and family practice doctors who wish to provide their patients with the best possible care.
For the Editors, the task of writing a Preface is most satisfying. It represents the completion of the book and a moment of reflection on whether the whole is more than the sum of all the parts. And also, one must reflect on how this book is likely to be utilized in this era of rapid communications. The Editors first met in May 2003 at a stimulating Italian symposium on endometrial cancer (organizers Drs. Luigi Frigerio, Roberto Grassi and Andrea Lissoni, with participation of the deans of Italian Gynecologic Oncology, Ugo Bianchi and Constantino Mangioni) that took place at Bergamo and Caravaggio. The impressive gains in biology and clinical trials were further discussed by the two editors and others that are co-authors in this venture on this side of the Atlantic at a 2004 Educational Session at the American Society of Clinical Oncology (ASCO). The pace of progress in various aspects of management of uterine cancer was no- worthy, not only was tumor biology fueling novel hypotheses such as questioning the mesenchymal origin of carcinosarcomas, but knowledge of molecular pathways was beginning to be applied as prognostic and as predictive factors portending benefit from systemic therapies. Surgical staging and sensitive imaging provided the underpinning for refining our treatment algorithms. Finally, a role for che- therapy had finally become established, principally through phase III studies c- paring chemotherapy to radiation in mostly locally advanced stages III and IV that had undergone resection.
|
You may like...
Menasseh Ben Israel's Mission to Oliver…
1604-1657 Manasseh Ben Israel
Hardcover
R880
Discovery Miles 8 800
|